Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 12,380 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 12,380 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the completion of the sale, the director owned 13,689,166 shares in the company, valued at $482,953,776.48. This represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00.
• On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The shares were sold at an average price of $34.00, for a total value of $21,276,622.00.

Roivant Sciences Stock Performance

Shares of ROIV opened at $35.39 on Wednesday. The firm has a market capitalization of $25.45 billion, a P/E ratio of -58.98 and a beta of 1.13. Roivant Sciences Ltd. has a 52 week low of $10.70 and a 52 week high of $35.90. The stock has a 50 day moving average price of $29.88 and a two-hundred day moving average price of $27.02.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The company had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. On average, equities analysts forecast that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. UBS Group AG grew its stake in shares of Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after acquiring an additional 15,645,836 shares during the period. Morgan Stanley lifted its holdings in Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after purchasing an additional 14,036,696 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Roivant Sciences by 365.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after purchasing an additional 8,621,567 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Roivant Sciences by 11,507.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after purchasing an additional 6,877,348 shares during the period. Finally, Norges Bank purchased a new position in shares of Roivant Sciences in the fourth quarter worth about $112,750,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ROIV shares. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. Guggenheim raised their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. Citigroup increased their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Finally, Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.